Therefore, on the one hand, inhibiting the Polθ gene in HR-deficient tumors induces tumor cell death through a “synthetic lethal” mechanism, and on the other hand, targeting PARPi-resistant cells caused by 53BP1/Shieldin complex deficiency, is a promising strategy for the treatment of PARPi-resistant patients. This evidence concerns the gene TP53BP1 and neoplasm.